Literature DB >> 3241123

Warfarin administration reduces synthesis of sulfatides and other sphingolipids in mouse brain.

K S Sundaram1, M Lev.   

Abstract

The modulation of phosphosphingolipid synthesis by vitamin K depletion has been observed in the vitamin K-dependent microorganism, Bacteriodes levii. When cultured briefly without the vitamin, a reduction occurred in the activity of the first enzyme of the sphingolipid pathway, 3-ketodihydrosphingosine synthase. In this report, 16-day-old mice were treated with the vitamin K antagonist, warfarin. Brain microsomes from these animals showed a 19% reduction in synthase activity. Mice treated with warfarin for 2 weeks showed a major reduction in sulfatide level (42%), with a lesser degree or no reduction in levels of gangliosides and cerebrosides. In further experiments, mice were treated with warfarin for 2 weeks and a group was then injected with vitamin K1 (aquamephyton) for 3 days. Enzyme activity returned to a normal level within 2-3 days. Sulfatide levels had increased 33% in the vitamin K-injected group and ganglioside levels also increased, where levels of cerebrosides and sphingomyelin declined. Sulfatide synthesis determined by [35S] sulfate incorporation, showed a 52% increase in incorporation following administration of vitamin K for 3 days. These results suggest a role for vitamin K in the biosynthesis of sulfatides and other sphingolipids in brain. This putative role could be by post-translational protein modification analogous to the role of vitamin K in other systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3241123

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  17 in total

1.  Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues.

Authors:  J D Kulman; J E Harris; L Xie; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

Review 3.  The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.

Authors:  Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg
Journal:  Ann N Y Acad Sci       Date:  2016-05-31       Impact factor: 5.691

Review 4.  Vitamin K and the nervous system: an overview of its actions.

Authors:  Guylaine Ferland
Journal:  Adv Nutr       Date:  2012-03-01       Impact factor: 8.701

5.  Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study.

Authors:  Guylaine Ferland; Catherine Feart; Nancy Presse; Simon Lorrain; Fabienne Bazin; Catherine Helmer; Claudine Berr; Cedric Annweiler; Olivier Rouaud; Jean-François Dartigues; Annie Fourrier-Reglat; Pascale Barberger-Gateau
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-11-17       Impact factor: 6.053

6.  The long-term administration of L-cycloserine to mice: specific reduction of cerebroside level.

Authors:  K S Sundaram; M Lev
Journal:  Neurochem Res       Date:  1989-03       Impact factor: 3.996

7.  Vitamin k antagonist warfarin for palliative treatment of metachromatic leukodystrophy, a compassionate study of four subjects.

Authors:  Mitra Assadi; Dah-Jyuu Wang; Kelly Anderson; Melissa Carran; Larissa Bilaniuk; Paola Leone
Journal:  J Cent Nerv Syst Dis       Date:  2012-04-26

Review 8.  The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease.

Authors:  Marcus O W Grimm; Janine Mett; Tobias Hartmann
Journal:  Int J Mol Sci       Date:  2016-10-26       Impact factor: 5.923

Review 9.  Developing therapeutic approaches for metachromatic leukodystrophy.

Authors:  Shilpa A Patil; Gustavo H B Maegawa
Journal:  Drug Des Devel Ther       Date:  2013-08-08       Impact factor: 4.162

10.  Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.

Authors:  Hiroshi Deguchi; Silvia Navarro; Amanda B Payne; Darlene J Elias; Nicole F Dowling; Harland D Austin; Francisco España; Pilar Medina; W Craig Hooper; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.